NMLB-101

NMLB-101 is a first-in-class, allosteric small molecule inhibitor targeting the Raf kinase pathway, specifically identified as PanmKRaf TN2. Developed by Atomwise (now operating as Numerion Labs) using AI-powered drug discovery platforms, the compound is designed to modulate inflammatory signaling pathways. It is currently being investigated in Phase 1 clinical development for the treatment of autoimmune and inflammatory conditions, including Inflammatory Bowel Disease (IBD) and Lupus (Systemic Lupus Erythematosus). The drug's allosteric mechanism of action aims to provide high selectivity and potency in inhibiting the Raf kinase complex, which is a critical node in the MAPK/ERK signaling cascade involved in immune response regulation.